SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2022 / Cilt: 4 - Sayı: 4

Comparison of the expression of GATA-3 protein from the transcription factor family and pathological prognostic parameters in invasive ductal carcinomas of the breast

Leymune PARLAK
Olcay KANDEMİR
Pages
163–173
Publication Date
2022-10-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

They can be used to identify both primary and secondary breast tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background GATA binding protein 3 (GATA-3) is one of the six transcription factor family members and is important for glandular development in the breast.
📊
Key Findings & Data:We aimed to compare GATA-3 immunoreactivity and pathological prognostic factors in patients with invasive ductal carcinoma.
💡
Conclusion & Impact:They can be used to identify both primary and secondary breast tumors.
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:GATA-3 · Breast cancer · Prognostic markers

Abstract

Background GATA binding protein 3 (GATA-3) is one of the six transcription factor family members and is important for glandular development in the breast. Its expression becomes important in breast cancer. We aimed to compare GATA-3 immunoreactivity and pathological prognostic factors in patients with invasive ductal carcinoma. Material and Methods Our study was conducted retrospectively with 300 breast invasive ductal carcinoma patients who were operated on in our hospital between May 2013 and June 2014. Patient reports, slides and blocks in the pathology archive were scanned. GATA-3 immunohistochemical (IHC) staining was evaluated according to the nuclear staining, intensity and percentage. The relationship between clinicopathological prognostic parameters and GATA-3 IHC staining results was investigated. Results A positive staining was observed in 286 (95.3%) cases. According to the GATA-3 staining intensity and percentage, 210 (70%) cases stained strongly and 246 (82%) stained +4, respectively. There was a significant relationship between GATA-3 immunoreactivity with ER, PR, Cerb-B2, Ki-67, mitotic degree, mitotic count and histological grade. Conclusions There was a correlation between the high expression of GATA-3 and good prognostic markers. Hormone receptors can be evaluated with Cerb-B2 and Ki-67 and used as prognosis determinants in breast cancers. They can be used to identify both primary and secondary breast tumors.

🔖

Cite This Article

PARLAK, L., KANDEMİR, O. (2022). Comparison of the expression of GATA-3 protein from the transcription factor family and pathological prognostic parameters in invasive ductal carcinomas of the breast. Turkish Journal of Internal Medicine, Cilt: 4 - Sayı: 4, 163–173. https://ajindex.com/articles/808950

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Güneş ME, Çelik G, Trabulus FD, Aksoy Ş, Özoran E, Aren A, Gücin Z, Bahadır F. Üçlü (ER, PGR, HER2) negatif 47 meme kanserli hastanın değerlendirilmesi. Istanbul Tıp Dergisi (Istanbul Med J). 2012;13(4):166-8 (in Turkish). doi: 10.5505/1304.8503.2012.96158. Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguère V, Siegel PM, Bouchard M. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene. 2009 Jul 23;28(29):2634-42. doi: 10.1038/onc.2009.126. Tozbikian GH, Zynger DL. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. Hum Pathol. 2019 Mar;85:221-7. doi: 10.1016/j.humpath.2018.11.005. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010 Jan;222(1):42-9. doi: 10.1002/jcp.21943.
  2. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006 Dec 1;127(5):1041-55. doi: 10.1016/j.cell.2006.09.048. Yu S, Jiang X, Li J, Li C, Guo M, Ye F, Zhang M, Jiao Y, Guo B. Comprehensive analysis of the GATA transcription factor gene family in breast carcinoma using gene microarrays, online databases and integrated bioinformatics. Sci Rep. 2019 Mar 14;9(1):4467. doi: 10.1038/s41598-019-40811-3.
  3. Takaku M, Grimm SA, Wade PA. GATA3 in breast cancer: Tumor suppressor or oncogene? Gene Expr. 2015;16(4):163-8. doi: 10.3727/105221615X14399878166113. Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S, Mah V, Bose S, Chia D, Chang HR, Goodglick L. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol. 2010 Dec;41(12):1794-801. doi: 10.1016/j.humpath.2010.06.010. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005 Dec 15;65(24):11259-64. doi: 10.1158/0008-5472.CAN-05-2495.
  4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Zheng R, Blobel GA. GATA Transcription factors and cancer. Genes Cancer. 2010 Dec;1(12):1178-88. doi: 10.1177/1947601911404223. Wendroth SM, Mentrikoski MJ, Wick MR. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin. Ann Diagn Pathol. 2015 Feb;19(1):6-9. doi: 10.1016/j.anndiagpath.2014.12.001.